Since targeting either EGFR or MET does not provide significant prognostic benefit for HNSCC patients [24,[34], [35], [36], [37]], we tested the assumption that single-agent targeted inhibition of GFRs is not effective due to redundant oncogenic GFR activity mediated by FER. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.